Literature DB >> 11323323

Incidence of herpes simplex virus type 2 infection in the United States.

G L Armstrong1, J Schillinger, L Markowitz, A J Nahmias, R E Johnson, G M McQuillan, M E St Louis.   

Abstract

Between the time that two large, national surveys were conducted, the Second National Health and Nutrition Examination Survey (1976-1980) and the Third National Health and Nutrition Examination Survey (1988-1994), prevalence of herpes simplex virus type 2 (HSV-2) infection in the United States increased by 30%. From these survey data, the authors estimated the incidence of HSV-2 infection in the civilian, noninstitutionalized population aged > or = 12 years by means of a mathematical model that allowed overall incidence to increase linearly with time but required the shape of the age-specific incidence curve to remain constant. From 1970 to 1985, annual incidence of HSV-2 infection in HSV-2-seronegative persons increased by 82%, from 4.6 per 1,000 (95% confidence interval: 4.2, 5.0) to 8.4 per 1,000 (95% confidence interval: 7.7, 9.1). Incidence in 1985 was higher in women than in men (9.9 vs. 6.9 per 1,000), higher in Blacks than in Whites (20.4 vs. 6.3 per 1,000), and highest in the group aged 20-29 years (14.6 and 22.5 per 1,000 in men and women, respectively). Thus, by 1985, approximately 1,640,000+/-150,000 persons (730,000 men and 910,000 women) were being infected annually with HSV-2.

Entities:  

Mesh:

Year:  2001        PMID: 11323323     DOI: 10.1093/aje/153.9.912

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  26 in total

1.  Use of a single monoclonal antibody to determine the susceptibilities of herpes simplex virus type 1 and type 2 clinical isolates to acyclovir.

Authors:  Christine Chutkowski; Betty Olson; Ann McDonough; James Mahoney; James J McSharry
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

2.  Performance and use of a ribonucleotide reductase herpes simplex virus type-specific serological assay.

Authors:  S Q Wales; C C Smith; M Wachsman; G Calton; L Aurelian
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

3.  Therapeutic Options for Herpes Simplex Infections.

Authors:  Eugene Au; Stephen L. Sacks
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

4.  Genetic factors influence serological measures of common infections.

Authors:  Rohina Rubicz; Charles T Leach; Ellen Kraig; Nikhil V Dhurandhar; Ravindranath Duggirala; John Blangero; Robert Yolken; Harald H H Göring
Journal:  Hum Hered       Date:  2011-10-11       Impact factor: 0.444

5.  Fulminant hepatic failure in a newborn with herpes simplex virus 2 infection.

Authors:  Sascha Meyer; Gisela Enders; Ali Baghai; Günther Löffler; Ludwig Gortner; Sven Gottschling
Journal:  Eur J Pediatr       Date:  2005-07-26       Impact factor: 3.183

6.  The lack of RNA-dependent protein kinase enhances susceptibility of mice to genital herpes simplex virus type 2 infection.

Authors:  Daniel J J Carr; Todd Wuest; Lisa Tomanek; Robert H Silverman; Bryan R G Williams
Journal:  Immunology       Date:  2006-08       Impact factor: 7.397

7.  Risk of herpes simplex virus type 2 acquisition increases over early adulthood: evidence from a cohort study.

Authors:  N Dickson; T van Roode; P Herbison; J Taylor; A Cunningham; C Paul
Journal:  Sex Transm Infect       Date:  2006-08-17       Impact factor: 3.519

8.  SEROPREVALENCE AND RISK FACTORS OF HERPES SIMPLEX VIRUS TYPE 2 AMONGST PATIENTS' ATTENDING RETROVIRAL CLINIC IN FEDERAL MEDICAL CENTER ABEOKUTA, SOUTH-WEST NIGERIA.

Authors:  V U Nwadike; P Osinupebi; O Y Ojo; G B Imhonopi; O A Oyesola; C J Elikwu; W O Oladosu
Journal:  Ann Ib Postgrad Med       Date:  2020-06

Review 9.  Herpes simplex virus type 2 vaccines: new ground for optimism?

Authors:  L Aurelian
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

10.  Costs and effectiveness of neonatal male circumcision.

Authors:  Seema Kacker; Kevin D Frick; Charlotte A Gaydos; Aaron A R Tobian
Journal:  Arch Pediatr Adolesc Med       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.